#ARDX

3 days ago

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award Ardelyx (Nasdaq: ARDX) announced the five recipients of the 2026 Derek Forfang Patient Advocate Award on March 12, 2026. Honorees Edward Drake II, Markesha Grayson, Timmy Nelson, Pesh Patel and Glenda Roberts were selected for sustained advocacy on behalf of people with chronic kidney disease.Recipients will be honored at the National Kidney Foundation Spring Clinical Meetings in New Orleans; the award recognizes contributions in outreach, policy, education and patient-centered research engagement.

#ARDX Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

www.stocktitan.net/news/ARDX/ardelyx-announ...

0 0 0 0

StockTitan

@stocktitan.net

6 days ago

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical

#ARDX Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

www.stocktitan.net/news/ARDX/ardelyx-announ...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

2 weeks ago

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership | The Motley Fool Ardelyx is coming off a strong Q4 earnings report for fiscal year 2025. But how is the stock performing?

#ARDX #674653ab-c6e3-4dd9-b633-c3b0c8d4cf2a #coveragefilings #Health #Care

Origin | Interest | Match

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook Ardelyx (Nasdaq: ARDX) reported preliminary, unaudited 2025 product revenue of approximately $378 million with IBSRELA generating about $274 million$104 million for 2025 with ~$28 million in Q4. The company ended 2025 with $265 million in cash, cash equivalents and investments. Guidance: 2026 IBSRELA revenue is expected at $410–430 million (≥50% growth vs. 2025) and XPHOZAH at $110–120 million. Long-term outlook projects IBSRELA reaching $1 billion revenue by 2029. Corporate updates include a Phase 3 CIC trial commencing and a Notice of Allowance for a patent expiring December 6, 2041.

#ARDX Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

www.stocktitan.net/news/ARDX/ardelyx-report...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week Ardelyx (Nasdaq: ARDX) presented real-world and clinical analyses of XPHOZAH (tenapanor) at ASN Kidney Week on November 7, 2025. Key findings: real-world initiators experienced an average serum phosphate reduction of ~1.0 mg/dL, with 45.3% of patients reducing ≥1 mg/dL and 25.1% reducing ≥2 mg/dL over a 120-day follow-up. A patient survey reported 63% felt phosphate levels were better and 69% reported improved outlook on control. Additional posters showed improved bowel movements in ESKD patients and a Japan cost-effectiveness analysis meeting a 5 million JPY willingness-to-pay threshold.

#ARDX Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

www.stocktitan.net/news/ARDX/real-world-evi...

1 0 0 0

StockTitan

@stocktitan.net

4 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting Ardelyx (Nasdaq: ARDX) presented real-world and clinical analyses of IBSRELA (tenapanor) at the ACG 2025 Annual Meeting (Oct 28, 2025). Key findings include high patient-reported treatment satisfaction (88%), reported improvements in constipation (95%), bloating (75%) and abdominal pain (84%), and 76% saying IBSRELA is better than prior IBS-C medications. Phase 3 T3MPO-1/2 post-hoc analyses show clinically meaningful bloating reduction as early as week one and sustained benefit. An EHR study found reductions in GI visits and patient portal messaging after tenapanor initiation among high healthcare resource users, suggesting potential to lower HCRU.

#ARDX Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting

www.stocktitan.net/news/ARDX/ardelyx-presen...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Ardelyx Q2 Revenue Jumps 33% | The Motley Fool

#ARDX #91dbaf96-0145-4830-99e8-fbebf5254708 #data-news

Origin | Interest | Match

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Ardelyx Crushes Earnings: 84% Product Growth Drives Massive Guidance Boost for 2025 Strong Q2 results show 33% revenue growth to $97.7M, with IBSRELA sales soaring 84%. Company raises full-year guidance. See complete financial details.

#ARDX Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/ARDX/ardelyx-report...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

9 months ago

Investigating Securities Fraud Claims Against Ardelyx, Inc.: What Investors Should Know Pomerantz Law Firm is launching an investigation into potential securities fraud involving Ardelyx, Inc. Investors should stay informed.

Investigating Securities Fraud Claims Against Ardelyx, Inc.: What Investors Should Know #United_States #New_York #Pomerantz_Law #Ardelyx #ARDX

0 0 0 0

The Insiders Fund Hedge Fund Guy

@insomniachedgefund.bsky.social

10 months ago

Insider Buying Week 05-09-25 Bargain Basement Week Finally, a busy week. I can’t extrapolate anything about the general market from these buys, but it’s clear that some […]

current environment?
#InsiderBuying #ARDX #Biotech #Pharmaceuticals #NotInvestmentAdvice
For more insider buying analysis: www.theinsidersfund.com/2025/05/insi...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

Pomerantz Law Firm Opens Investigation into Ardelyx, Inc. for Possible Securities Fraud Claims Pomerantz LLP initiates an investigation into Ardelyx, Inc., focusing on allegations of securities fraud following disappointing financial results.

Pomerantz Law Firm Opens Investigation into Ardelyx, Inc. for Possible Securities Fraud Claims #United_States #New_York #Pomerantz #Ardelyx #ARDX

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Triple Study Results: IBSRELA IBS-C Drug Proves Safe for Teens and Nursing Mothers at DDW 2025 New clinical findings reveal IBSRELA's safety profile in pediatric patients and nursing mothers, plus IBS-C financial impact data. See complete trial results.

#ARDX Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

www.stocktitan.net/news/ARDX/ardelyx-presen...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update Ardelyx (ARDX) reported strong Q1 2025 financial results with total revenue of $74.1 million, representing 61% growth year-over-year. Key highlights include IBSRELA net product sales of $44.4 million (57% YoY growth) and XPHOZAH net product sales of $23.4 million. The company maintained a solid financial position with $214.0 million in cash and investments. IBSRELA's full-year 2025 revenue guidance remains between $240-250 million. Notable developments include tenapanor's approval in China for hyperphosphatemia, earning a $5.0 million milestone payment from Fosun Pharma. However, the company reported a net loss of $41.1 million ($0.17 per share) for Q1 2025, compared to $26.5 million loss in Q1 2024, primarily due to increased commercialization costs.

#ARDX Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/ARDX/ardelyx-report...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Breakthrough: New Analysis Reveals Better Outcomes for First-in-Class Kidney Drug XPHOZAH Latest analysis shows improved patient outcomes with XPHOZAH, the first FDA-approved phosphate absorption inhibitor for dialysis patients. Key findings inside.

#ARDX Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

www.stocktitan.net/news/ARDX/post-hoc-analy...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

First-in-Class Kidney Disease Drug XPHOZAH Reveals Breakthrough Clinical Results Latest analysis demonstrates XPHOZAH's effectiveness in managing phosphorus levels for dialysis patients, with improved side effect control. Full clinical insights inside.

#ARDX Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

www.stocktitan.net/news/ARDX/ardelyx-to-sha...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Five Champions of Kidney Disease Advocacy Receive Groundbreaking Ardelyx Recognition Five exceptional CKD patient advocates receive inaugural Derek Forfang Award on World Kidney Day, recognizing their transformative work in kidney disease awareness and healthcare policy.

#ARDX Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

www.stocktitan.net/news/ARDX/ardelyx-announ...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can Ardelyx's Newly Approved Kidney Disease Drug Transform China's Million-Patient Market? Approval triggers immediate $5M milestone with potential for $100M more plus royalties. China's dialysis market exceeds 1M patients with 76% suffering from hyperphosphatemia.

#ARDX Tenapanor Approved in China for Hyperphosphatemia

www.stocktitan.net/news/ARDX/tenapanor-appr...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Ardelyx (ARDX) reported strong financial results for FY 2024, with total revenue reaching $333.6 million, including $319.2 million in U.S. Net Product Sales. IBSRELA achieved $158.3 million in net product sales, while XPHOZAH recorded $160.9 million in its first full year of commercialization.The company ended 2024 with $250.1 million in cash and investments, up from $184.3 million in 2023. Net loss for 2024 was $39.1 million ($0.17 per share), improved from $66.1 million ($0.30 per share) in 2023. Ardelyx reaffirms combined peak sales expectations of $1.75 billion for both products, with IBSRELA projected to achieve over $1 billion and XPHOZAH expected to reach $750 million in annual U.S. net product sales before patent expiration.

#ARDX Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/ARDX/ardelyx-report...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Ardelyx Reports Strong 2024: IBSRELA, XPHOZAH Drive $319M Revenue as Growth Accelerates Ardelyx's commercial success continues with IBSRELA hitting $158M and XPHOZAH reaching $161M in 2024 sales. Company projects IBSRELA 2025 sales of $240-250M with $1B+ peak potential.

#ARDX Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities

www.stocktitan.net/news/ARDX/ardelyx-provid...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#ARDX Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/ARDX/ardelyx-to-par...

1 0 0 0